AbCellera Biologics Inc. (ABCL) distance from 20-day Simple moving Average is 25.37%: What to Expect? – Invest Chronicle

AbCellera Biologics Inc. (ABCL) distance from 20-day Simple moving Average is 25.37%: What to Expect?

AbCellera Biologics Inc. (ABCL) is priced at $10.29 after the most recent trading session. At the very opening of the session, the stock price was $9.67 and reached a high price of $10.71, prior to closing the session it reached the value of $9.81. The stock touched a low price of $9.611.Recently in News on May 10, 2022, AbCellera Reports Q1 2022 Business Results. Total revenue of $317 million, compared to $203 million in Q1 2021. You can read further details here

AbCellera Biologics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.79 on 01/03/22, with the lowest value was $5.42 for the same time period, recorded on 05/12/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


AbCellera Biologics Inc. (ABCL) full year performance was -53.38%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, AbCellera Biologics Inc. shares are logging -54.97% during the 52-week period from high price, and 89.85% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $5.42 and $22.85.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4336849 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the AbCellera Biologics Inc. (ABCL) recorded performance in the market was -28.04%, having the revenues showcasing 9.35% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.68B, as it employees total of 386 workers.

Analysts verdict on AbCellera Biologics Inc. (ABCL)

According to the data provided on, the moving average of the company in the 100-day period was set at 8.60, with a change in the price was noted +2.52. In a similar fashion, AbCellera Biologics Inc. posted a movement of +32.43% for the period of last 100 days, recording 2,081,906 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABCL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

AbCellera Biologics Inc. (ABCL): Technical Analysis

Raw Stochastic average of AbCellera Biologics Inc. in the period of last 50 days is set at 92.06%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 88.52%. In the last 20 days, the company’s Stochastic %K was 86.59% and its Stochastic %D was recorded 87.76%.

Let’s take a glance in the erstwhile performances of AbCellera Biologics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -28.04%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -29.52%, alongside a downfall of -53.38% for the period of the last 12 months. The shares increased approximately by 16.93% in the 7-day charts and went down by 30.25% in the period of the last 30 days. Common stock shares were driven by 9.35% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts